BioXcel Therapeutics (BTAI) Accumulated Expenses (2017 - 2026)

BioXcel Therapeutics' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 4890.62% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $6.4 million (up 4890.62% YoY), while the FY2025 annual figure was $34000.0, down 2.86% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.4 million, up from $34000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $26.6 million in Q3 2023, with the low at $34000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $1.9 million (2022), against an average of $5.7 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses slumped 99.85% in 2024, then surged 11087.18% in 2025.
• BioXcel Therapeutics' Accumulated Expenses stood at $3.2 million in 2022, then tumbled by 76.82% to $736000.0 in 2023, then slumped by 95.24% to $35000.0 in 2024, then dropped by 2.86% to $34000.0 in 2025, then soared by 18688.24% to $6.4 million in 2026.
• Business Quant data shows BTAI's Accumulated Expenses at $6.4 million in Q1 2026, $34000.0 in Q4 2025, and $4.4 million in Q3 2025.